500
Participants
Start Date
November 13, 2014
Primary Completion Date
January 30, 2019
Study Completion Date
January 30, 2019
Rivaroxaban (Xarelto, BAY59-7939)
Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
Rivaroxaban (Xarelto, BAY59-7939)
Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
Standard of Care
"LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care"
Crumlin
Vienna
Budapest
Bruxelles - Brussel
Edegem
Leuven
Bern
Parkville
San Miguel de Tucumán
Linz
South Brisbane
Lucerne
Innsbruck
Zurich
Graz
Turin
Berlin
A Coruña
Philadelphia
Milan
Turku
Durham
Atlanta
Toulouse
Jacksonville
Pensacola
Gainesville
Miami
St. Petersburg
Montpellier
Istanbul
Padua
Konya
Indianapolis
Lansing
Chicago
Paris
Dallas
Fort Worth
Houston
Phoenix
Los Angeles
Erlangen
San Diego
Beijing
Beijing
Moscow
Moscow
Singapore
Saint Petersburg
Saint Petersburg
Krasnodar
Volgograd
Kazan'
Nizhny Novgorod
Yekaterinburg
Kemerovo
Afula
Petah Tikva
Ramat Gan
Jerusalem
Little Rock
Los Angeles
Kansas City
Cincinnati
Cleveland
Columbus
Campinas
São Paulo
São Paulo
São Paulo
Calgary
Edmonton
Hamilton
Ottawa
Toronto
Montreal
Hangzhou
Shanghai
Hong Kong
Guadalajara
Dresden
Halle
Ōbu
Azumino
Bunkyo-ku
Mexico City
Amsterdam
Groningen
Nijmegen
Rotterdam
Utrecht
Carnaxide
Singapore
Bratislava
Esplugues de Llobregat
Barcelona
Solna
Adana
Newcastle upon Tyne
Birmingham
Leeds
Cardiff
Edinburgh
Glasgow
London
Manchester
Oxford
Sheffield
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY